USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AMT, INC.
Address:
508 HEARTWOOD RD
CHERRY HILL, NJ 08003
CHERRY HILL, NJ 08003
Phone:
(609) 795-4560
URL:
N/A
EIN:
222933446
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $677,688.00 11
SBIR Phase II $638,167.00 2
STTR Phase I $100,000.00 2
STTR Phase II $278,132.00 1

Award List:

STABLE ANTITUMOR PLATINUM COMPLEXES

Award Year / Program / Phase:
1983 / SBIR / Phase I
Award Amount:
$72,380.00
Agency:
HHS
Principal Investigator:
Paul Schwartz
Abstract:
N/a

NOVEL APPROACHES TO FASIL POLYMERS

Award Year / Program / Phase:
1983 / SBIR / Phase I
Award Amount:
$59,891.00
Agency / Branch:
DOD / USAF
Principal Investigator:
Abstract:
N/a

NOVEL APPROACHES TO FASIL POLYMERS

Award Year / Program / Phase:
1984 / SBIR / Phase II
Award Amount:
$305,000.00
Agency / Branch:
DOD / USAF
Principal Investigator:
Abstract:
Fluorroalkylarylenesiloxanylene (fasil) polymers possess excellent themal stability, low emperatue, and hydrocarbon solvent resistance. polymers based on fasil have extensive promise for military and commercial aerospace applications if they could be reliably and efficiently produced. the program… More

STABLE ANTITUMOR PLATINUM COMPLEXES

Award Year / Program / Phase:
1985 / SBIR / Phase II
Award Amount:
$333,167.00
Agency:
HHS
Principal Investigator:
Paul Schwartz
Abstract:
The objective of this study is to prepare antineoplastic platinum complexes with stabilities in solution greater thanthat of 4-carboxyphthalato(1,2-diaminocyclohexane) platinum (nsc 271674;dachpt). nsc 271674 is a cisplatin analog invented by the applicant and now in phase ii clinical trials at… More

THE PROVEN CLINICAL EFFECTIVENESS OF CISPLATIN AS WELL AS SEVERAL SECOND GENERATION ANALOGS HAS ESTABLISHED THE ROLE OF METAL COORDINATION COMPOUNDS IN CANCER CHEMOTHERAPY.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$49,885.00
Agency:
HHS
Principal Investigator:
Devinder gill , PRINCIPAL INVESTIGATOR
Abstract:
The proven clinical effectiveness of cisplatin as well as several second generation analogs has established the role of metal coordination compounds in cancer chemotherapy. complexes of metals other than platinum have been often poorly designed because they were modeled after the active platinum… More

THE OBJECTIVE OF THIS STUDY IS TO SYNTHESIZE, CHARACTERIZE, AND EVALUATE BIOLOGICAL PROPERTIES OF POLYMERIC PLATINUM COMPLEXES IN AN EFFORT TO ENHANCE SOLUBILITY AND STABILITY WHILE REDUCING TOXICITY AND OBTAINING GREATER SUSTAINED ACTIVITY THAN THAT

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$49,839.00
Agency:
HHS
Principal Investigator:
Devinder gill , PRINCIPAL INVESTIGATOR
Abstract:
The objective of this study is to synthesize, characterize, and evaluate biological properties of polymeric platinum complexes in an effort to enhance solubility and stability while reducing toxicity and obtaining greater sustained activity than that found with active, structurally related,… More

THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Peter andrulis jr , PRINCIPAL INVESTIGATOR
Abstract:
The complex 4-carboxyphthalato (1, 2-diaminocyclohexane) platinum (nsc 271674; dach-pt) has undergone limited clinical trials. designed as an alternative therapy to cisplatin, it has demonstrated substantially reduced toxicity and enhanced activity in tumors resistant to cisplatin in animals… More

NEW TARGET-DIRECTED PT-PORPHYRIN ANTICANCER DRUGS

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$46,000.00
Agency:
HHS
Principal Investigator:
Paul schwartz phd
Abstract:
The objective of this project is to improve the selectivity of action of platinum antitumor agents. platinum compounds have shown activity in many types of tumors, but severe dose-limiting side effects have affected their clinical utility. by directing these agents more specifically to tumor sites,… More

MECHANISM-BASED ELASTASE INHIBITORS

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Clare biswas phd
Abstract:
Synthetic elastase inhibitors for use in the treatment of emphysema will be developed. in phase i, new mechanism-based elastase inhibitors will be synthesized, characterized, and studied as inhibitors of elastase in vitro. these inhibition studies will analyze both the reversible behavior of the… More

POLYMERIC DELIVERY SYSTEMS FOR ANTIRETROVIRAL AGENTS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,855.00
Agency:
HHS
Principal Investigator:
Devinder S Gill
Abstract:
The goal of this phase i research is to design, synthesize, develop, and evaluate the in vitro efficacy of a new class of polymeric "targeted" prodrugs of azt. the overall objective of this program is to create new anti-aids prodrugs that will possess markedly enhanced antiviral activity, low… More

SOLUBILIZATION AND SUSTAINED DELIVERY OF ANTITUMOR AGENTS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,838.00
Agency:
HHS
Principal Investigator:
Devinder S Gill
Abstract:
The overall objective is to provide a new drug delivery system and to enhance the solubility of existing compounds that exhibit excellent antitumor properties but are insoluble in water. aqueous solubility is essential for i.v. administration of antitumor drugs. phase i research will solubilize… More

MICROWAVE AIDED LIPOSUCTION

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Rosen, Danielle
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Danielle Rosen
Abstract:
N/a

ENDOSCOPIC LIGHT SOURCE FOR PDT

Award Year / Program / Phase:
2001 / STTR / Phase II
Award Amount:
$278,132.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF PENNSYLVANIA
RI Contact:
N/A
Abstract:
DESCRIPTION (Verbatim from the Applicant's Abstract): We propose to continue to develop and test a self-contained light delivery device for use in photodynamic therapy (PDT) for Barrett's esophagus. This device employs distally located semiconductor lasers at the end of a thin… More